Pricing Log in Create free account
Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue
+36.3%
EPS
+36.0%
Free cash flow
+3.85%
Total debt
−26.6%

Quarter to September 2026, against a year earlier

907.78 4.88 +0.54%
Market cap
$93.4B
P/E
19.2×
Fwd P/E
19.2×
Dividend yield
0.41%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) Revenue growth

Alert me on Revenue growth

Regeneron Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 18.6%, up 17.6 percentage points from fiscal 2025 (0.99%). Over the past ten years it has ranged from −24.3% (fiscal 2022) to 89.1% (fiscal 2021); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 0.99% (7.28)
FY2024 8.27% 0.51
FY2023 7.76% 32.02
FY2022 −24.3% (113.40)
FY2021 89.1% 59.56
FY2020 29.6% 2.14
FY2019 27.4% 39.81
FY2018 −12.4% (33.19)
FY2017 20.8% 2.38
FY2016 18.4% (27.11)

Quarterly newest first

Period Revenue growth Change (points)
Sep 2026 36.3% 19.54
Jun 2026 16.7% (2.31)
Mar 2026 19.0% 16.53
Dec 2025 2.51% 1.61
43 more quarters

Against its own ten years

Low −24.3% High 89.1%
Ten-year median 18.4%
Current reading's percentile 27

Revenue growth against peers

Company Revenue growth
RVMD Revolution Medicines, Inc. compare 491.1%
ARGX argenex SE compare 60.8%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 32.9%
GMAB Genmab A/S Sponsored ADR compare 22.3%
REGN Regeneron Pharmaceuticals, Inc. 18.6%
RPRX Royalty Pharma PLC compare 11.4%
VRTX Vertex Pharmaceuticals Incorporated compare 10.5%
MRNA Moderna, Inc. compare −27.6%
ROIV Roivant Sciences Ltd. compare −67.6%
Biotechnology industry median 6.26%
Healthcare sector median 7.80%
Market median 7.58%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on REGN